Drug Trial Radar · NCT06861088
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Dec 19, 2025
Primary completion
Oct 31, 2027
Study completion Oct 31, 2029
Sponsor
- Lead sponsor
- Quercis Pharma AGIndustry
- Sponsor type
- Industry
- First posted
- Mar 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
Conditions
- Venous Thromboembolism
- Metastatic Pancreatic Cancer
- Locally Advanced Pancreatic Adenocarcinoma
Interventions
Kinisoquin™Drug
Kinisoquin™ capsules formulated with vitamin C and vitamin B3
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effectiveness of Kinisoquin™Time frame: 16 weeks
- Effectiveness of Kinisoquin™Time frame: 16 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Ventura Clinical Trials
Ventura, California · Recruiting
Clavis Medical, LLC
Miami Lakes, Florida · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.